NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Beijing Fiveplus Gene Technology

Beijing Fiveplus Gene Technology

Private
BeijingHealthcare & Life Scienceshttp://fiveplusgene.com.cn/

Last Round

M&A

Jun 15, 2023

Total Funding Raised

$4.65M

Company Overview

Beijing Fiveplus Gene Technology is a biotechnology company that provides end-to-end contract development and manufacturing organization (CDMO) services for gene therapy medicine research and development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Pharma Supply Chain

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

gene therapy CDMOviral vector manufacturingCDMOgene therapyCGT CDMOviral vectorscell and gene therapyGMP manufacturingprocess developmentAAV manufacturingplasmid manufacturingclinical trial manufacturingcontract development and manufacturing organizationaseptic fill/finish

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Beijing Fiveplus Gene Technology Comparables

Compare Beijing Fiveplus Gene Technology with similar companies based on industry and business-model similarity.

Beijing Fiveplus Gene Technology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zhejiang Innoforce Pharmaceuticals
86%
uBriGene Biosciences
84%
PackGene Biotech
82%

Beijing Fiveplus Gene Technology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AJun 15, 2023
Series ASep 28, 2021

Beijing Fiveplus Gene Technology Investors

Notable investors and investment history

Beijing Fiveplus Gene Technology investors
InvestorRounds
杭州怀济私募基金管理有限公司Series A
Hangzhou Aopeng Investment Management Co., Ltd.Series A

Beijing Fiveplus Gene Technology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Beijing Fiveplus Gene Technology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Beijing Fiveplus Gene Technology's valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Year Founded2018
Last FundingJun 15, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.